← Back to Search

Opioid Antagonist

Rapid Induction Procedure (RP) for Opioid Use Disorder (SWIFT Trial)

N/A
Waitlist Available
Research Sponsored by New York State Psychiatric Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years of age or older.
Seeking treatment for opioid use disorder, willing to accept treatment with XR- NTX and, in the judgment of the treating physician, is a good candidate for naltrexone- based treatment.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up induction phase- 1 - 30 days, post induction phase- 1-8 weeks
Awards & highlights

SWIFT Trial Summary

This trial is comparing two methods for starting treatment with extended-release naltrexone to see if the rapid method is non-inferior to the standard method.

Eligible Conditions
  • Opioid Use Disorder

SWIFT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

SWIFT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~induction phase- 1 - 30 days, post induction phase- 1-8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and induction phase- 1 - 30 days, post induction phase- 1-8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The Percentage of Patients Who Receive the First XR-NTX Injection (Dichotomous: Did or Did Not Receive First Dose of XR-NTX)
Secondary outcome measures
Frequency of Targeted Safety Events Related to Study Medication and Any Serious Adverse Events During Induction Period and During Eight Weeks of Post-induction Treatment
Mean for Individual Participant's General Anxiety Disorder (GAD-7) Score During Induction Phase
Mean for Individual Participant's General Anxiety Disorder (GAD-7) Score During Post-induction Weeks 1 Through 8
+16 more

SWIFT Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Rapid Induction MethodExperimental Treatment1 Intervention
The Rapid Method includes one day of buprenorphine followed by a day of washout and 3-4 days of oral naltrexone titration with adjunctive medications
Group II: Standard Induction MethodActive Control1 Intervention
The Standard Method (13-day long) includes 5-days of buprenorphine taper followed by 7-day washout period

Find a Location

Who is running the clinical trial?

New York State Psychiatric InstituteLead Sponsor
474 Previous Clinical Trials
152,842 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,459 Previous Clinical Trials
2,596,881 Total Patients Enrolled
The Emmes Company, LLCIndustry Sponsor
145 Previous Clinical Trials
1,051,076 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
American Journal of PsychiatryJournal
Long-acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification with Naltrexone Versus Buprenorphine
Sullivan, Maria, Adam Bisaga, Martina Pavlicova, C. Jean Choi, Kaitlyn Mishlen, Kenneth M. Carpenter, Frances R. Levin, Elias Dakwar, John J. Mariani, and Edward V. Nunes. 2017. “Long-acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification with Naltrexone Versus Buprenorphine”. American Journal of Psychiatry. American Psychiatric Association Publishing. doi:10.1176/appi.ajp.2016.16050548.
clinicaltrials.govStudy
Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone
Adam Bisaga 2021. "Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04762537.
~102 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top